ERBB2 and non-small cell lung carcinoma: In the phase II DESTINY-Lung-01 trial of T-DXd in unresectable and/or metastatic HER2-expressing NSCLC, the HER2-mutated cohort included 33 patients with stable BrMs and showed an intracranial ORR of 54.5% [96], while a intracranial response was not reported in the HER2-overexpressng cohort [97].